Accessibility Menu
Alterity Therapeutics logo

Alterity Therapeutics(NASDAQ) ATHE

Current Price$4.81
Market Cap$82.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)-99%
5 Year-66%
1 Year-20%
1 Month-10%
Alterity Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.542026-07-24
Alterity Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.84%USD 4.982026-07-17
1 month-10.37%USD 5.072026-06-24
3 month+2.95%USD 4.412026-04-24
Year to date+47.4%USD 3.082025-12-31
1 year-20.07%USD 5.682025-07-24
3 year+63.9%USD 2.772023-07-25
5 year-66.12%USD 13.402021-07-23
Since inception-99.33%USD 678.002002-09-05

Alterity Therapeutics Financials at a Glance

Market Cap

$82.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$7.56M

Net Income (TTM)

-A$34.20M

EPS (TTM)

-$18.69

P/E Ratio

-0.24

Dividend

$0.00

Beta (Volatility)

0.71 (Low)

Price

$4.81

Volume

184

Open

$4.81

Previous Close

$4.81

Daily Range

$4.81 - $4.81

52-Week Range

$2.66 - $6.03

Estimated Earnings Date

Aug 28, 2026

ATHE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alterity Therapeutics

Alterity Therapeutics Limited is an Australian biopharmaceutical company dedicated to developing innovative drug treatments for neurological disorders, including Alzheimer's, Huntington's, and Parkinson's diseases. The company is advancing its lead therapy, ATH434, which has completed Phase I clinical trials targeting Parkinson's disease, alongside PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease.

Products and Services
  • ATH434: A novel therapy for Parkinson's disease
  • PBT2: A compound targeting Alzheimer's disease
  • Research and development focused on neurological disorders
Growth Outlook
  • Strong pipeline with two promising drug candidates in clinical trials
  • Potential market expansion as neurological disorders increase globally
  • Strategic partnerships may enhance research capabilities and funding
Financial Highlights
  • Recent quarterly revenue of AUD 0, indicating ongoing investment in R&D
  • Cash and cash equivalents of AUD 49.15 million, providing operational stability
  • Current ratio of 21.98, reflecting strong liquidity position
Alterity Therapeutics Limited is positioned in the biotechnology sector, focusing on significant unmet medical needs in neurological disorders. The company has a robust pipeline with promising therapies that could address critical health challenges. Recent financial data indicates a strong liquidity position, which is essential for funding ongoing research and development efforts. The current ratio suggests that the company is well-equipped to meet its short-term obligations, providing a solid foundation for future growth. As the global prevalence of neurological disorders continues to rise, Alterity Therapeutics may play a crucial role in developing effective treatments, making it an intriguing option for potential investors.
AI Generated • Jun 30, 2026

Industry

Biotechnology

Sector

Health Care

Employees

9

CEO

David A. Stamler, MD

Website

www.alteritytherapeutics.com

Headquarters

Melbourne, VIC 3000, AU

ATHE Financials

Key Financial Metrics (TTM)

Gross Margin

96.82%

Operating Margin

-525.58%

Net Income Margin

-380.65%

Return on Equity

-30.19%

Return on Capital

-34.25%

Return on Assets

-25.63%

Earnings Yield

-4.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$82.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

18.14M

Volume

184

Avg. Volume

49.38K

Financials (TTM)

Gross Profit

A$7.30M

Operating Income

-A$40.38M

EBITDA

-A$42.01M

Operating Cash Flow

-A$29.25M

Capital Expenditure

A$10.43M

Free Cash Flow

-A$18.83M

Cash & ST Invst.

A$49.15M

Total Debt

A$98.35K

Alterity Therapeutics Performance Analysis

Alterity Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
Alterity Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3011.5%
Q22024-12-31-24.2%
Q42025-06-30138.7%
Q22025-12-31-100.0%
Alterity Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -116.19N/A
20232023-06-30AUD -114.83-1.2%
20242024-06-30AUD -2.06-98.2%
20252025-06-30AUD -0.74-64.2%
Alterity Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3023.1%
Q22024-12-3130.0%
Q42025-06-3050.0%
Q22025-12-31-28.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$56.83K

-103.1%

Gross Margin

0.00%

N/A

Market Cap

$82.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.15M

N/A

Employees

9

N/A

Net Income

-A$9.44M

-45.1%

EBITDA

-A$12.76M

-53.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$49.15M

+298.9%

Total Debt

A$98.35K

-61.5%

Accounts Receivable

A$6.84M

+17.7%

Inventory

A$0.00

N/A

Long Term Debt

A$65.40K

-14.5%

Short Term Debt

A$32.96K

-81.6%

Return on Assets

-25.63%

N/A

Return on Invested Capital

-37.08%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$10.43M

-131.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DYAIDyadic International, Inc.
$1.19-1.65%
GBIOGeneration Bio Co.
$5.34+0.00%
MURAMural Oncology plc
$2.04+0.00%
ANVSAnnovis Bio, Inc.
$1.66-5.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About ATHE

What is the current price of Alterity Therapeutics?

Alterity Therapeutics is trading at $4.81 per share.

What is the 52-week range for Alterity Therapeutics?

Over the past 52 weeks, Alterity Therapeutics has traded between $2.66 and $6.03.

How much debt does Alterity Therapeutics have?

As of the most recent reporting period, Alterity Therapeutics reported total debt of A$101.88K.

How much cash does Alterity Therapeutics have on hand?

Alterity Therapeutics reported A$21.73M in cash and cash equivalents in its most recent financial results.

What is Alterity Therapeutics’s dividend yield?

Alterity Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services